On October 23, 2024, BioVie Inc., a clinical-stage company focused on developing treatments for chronic debilitating conditions, announced the successful closing of a registered direct offering and a concurrent private placement. The offering involved the sale of 2,667,000 shares of Class A common stock at $2.25 per share, alongside warrants to purchase an equivalent number of shares at $2.12 per share. The gross proceeds from the offering amounted to approximately $6 million before deducting fees and expenses. BioVie intends to allocate the net proceeds for working capital and general corporate purposes. The shares were sold under a shelf registration statement previously filed with the SEC, and the warrants were offered in a private placement not subject to public offering registration requirements. ThinkEquity served as the sole placement agent for the transaction.

On October 23, 2024, BioVie Inc., a clinical-stage company focused on developing treatments for chronic debilitating conditions, announced the successful closing of a registered direct offering and a concurrent private placement. The offering involved the sale of 2,667,000 shares of Class A common stock at $2.25 per share, alongside warrants to purchase an equivalent number of shares at $2.12 per share. The gross proceeds from the offering amounted to approximately $6 million before deducting fees and expenses. BioVie intends to allocate the net proceeds for working capital and general corporate purposes. The shares were sold under a shelf registration statement previously filed with the SEC, and the warrants were offered in a private placement not subject to public offering registration requirements. ThinkEquity served as the sole placement agent for the transaction.